165 related articles for article (PubMed ID: 35933820)
21. Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus.
Braun M; Bjurnemark C; Seo W; Freyhult E; Nyholm D; Niemelä V; Blennow K; Zetterberg H; Fällmar D; Kultima K; Virhammar J
Fluids Barriers CNS; 2022 Feb; 19(1):15. PubMed ID: 35164790
[TBL] [Abstract][Full Text] [Related]
22. CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.
Jeppsson A; Wikkelsö C; Blennow K; Zetterberg H; Constantinescu R; Remes AM; Herukka SK; Rauramaa T; Nagga K; Leinonen V; Tullberg M
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1117-1123. PubMed ID: 31167811
[TBL] [Abstract][Full Text] [Related]
23. CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.
Oosterveld LP; Kuiper TI; Majbour NK; Verberk IMW; van Dijk KD; Twisk JWR; El-Agnaf OM; Teunissen CE; Weinstein HC; Klein M; Berendse HW; van de Berg WDJ
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198266
[TBL] [Abstract][Full Text] [Related]
24. Low soluble amyloid-β 42 is associated with smaller brain volume in Parkinson's disease.
Espay AJ; Lafontant DE; Poston KL; Caspell-Garcia C; Marsili L; Cho HR; McDaniel C; Kim N; Coffey CS; Mahajan A; Ezzat K; Sturchio A;
Parkinsonism Relat Disord; 2021 Nov; 92():15-21. PubMed ID: 34656902
[TBL] [Abstract][Full Text] [Related]
25. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
[TBL] [Abstract][Full Text] [Related]
26. Potential clinical utility of multiple system atrophy biomarkers.
Jellinger KA
Expert Rev Neurother; 2017 Dec; 17(12):1189-1208. PubMed ID: 29023182
[TBL] [Abstract][Full Text] [Related]
27. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
28. Misfolded α-Synuclein in Cerebrospinal Fluid of Contact Sport Athletes.
Vasilevskaya A; Martinez-Valbuena I; Anastassiadis C; Taghdiri F; Khodadadi M; Tarazi A; Green R; Colella B; Wennberg R; Mikulis D; Davis KD; Kovacs GG; Tator C; Tartaglia MC
Mov Disord; 2023 Nov; 38(11):2125-2131. PubMed ID: 37792643
[TBL] [Abstract][Full Text] [Related]
29. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
[TBL] [Abstract][Full Text] [Related]
30. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
[TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease.
Folke J; Rydbirk R; Løkkegaard A; Hejl AM; Winge K; Starhof C; Salvesen L; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
Parkinsonism Relat Disord; 2021 Jun; 87():98-104. PubMed ID: 34020303
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
[TBL] [Abstract][Full Text] [Related]
33. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
[TBL] [Abstract][Full Text] [Related]
34. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
35. Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study.
Singer W; Schmeichel AM; Sletten DM; Gehrking TL; Gehrking JA; Trejo-Lopez J; Suarez MD; Anderson JK; Bass PH; Lesnick TG; Low PA
Clin Auton Res; 2023 Dec; 33(6):635-645. PubMed ID: 37603107
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylated α-synuclein and phosphorylated tau-protein in sural nerves may contribute to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear paralysis.
Rong Z; Shen F; Wang Y; Sun L; Wu J; Zhang H; Yuan Y; Jiang W; Li X; Ji P; Zhang K
Neurosci Lett; 2021 Jun; 756():135964. PubMed ID: 34022266
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in tremor-dominant Parkinson's disease.
Nabizadeh F; Sodeifian F; Kargar A
Acta Neurol Belg; 2023 Aug; 123(4):1429-1437. PubMed ID: 37000407
[TBL] [Abstract][Full Text] [Related]
38. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
Milà-Alomà M; Salvadó G; Gispert JD; Vilor-Tejedor N; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; Crous-Bou M; González-de-Echávarri JM; Minguillon C; Fauria K; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL;
Alzheimers Dement; 2020 Oct; 16(10):1358-1371. PubMed ID: 32573951
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study.
Peng L; Wan L; Liu M; Long Z; Chen D; Yuan X; Tang Z; Fu Y; Zhu S; Lei L; Wang C; Peng H; Shi Y; He L; Yuan H; Wan N; Hou X; Xia K; Li J; Chen C; Qiu R; Tang B; Chen Z; Jiang H
J Neurol; 2023 Sep; 270(9):4248-4261. PubMed ID: 37184660
[TBL] [Abstract][Full Text] [Related]
40. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP.
Rojas JC; Bang J; Lobach IV; Tsai RM; Rabinovici GD; Miller BL; Boxer AL;
Neurology; 2018 Jan; 90(4):e273-e281. PubMed ID: 29282336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
